The National Hemophilia Foundation (NHF) Central Ohio Chapter is dedicated to finding cures for inheritable blood disorders and addressing and preventing the complications of these disorders through research, education, and advocacy enabling people and families to thrive.
Our Mission ... In Action
News & Announcements
On November 22, the U.S. Food and Drug Administration approved Hemgenix (etranacogene dezaparvovec), an adeno-associated virus (AAV) vector-based gene therapy. It is approved for the treatment of adults with hemophilia B who currently use factor IX (FIX) prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes.
Historically, many residential substance use disorder (SUD) facilities have denied admittance to individuals with bleeding disorders – the basis of these denials are most often the use of self-administered, intravenous medications such a as factor replacement therapies. The lack of access to residential addiction treatment facilities, can have very serious, even fatal outcomes for bleeding disorder (BD) patients in acute need of help with their addiction.
Joining the Chapter is Free!
We have a new and improved system of collecting membership information. Please make sure that every member in your household is listed. You will have to click next to get to the end of the form if you don't have any household members to add. Thank you for helping to keep our records current!
Also, while membership is free, you are still able to make a donation to the chapter if you wish. There is an option to donate at the end of the membership form.